CRWD -47.32AMD -19.52AVGO -70.07TVE.TO 0.42BHP -2.18BBD.B.TO -2.15OWL 0.695
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.76
+0.42 (1.64%)
as of Jun 4, 2026, 2:38:43 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY

Pfizer Inc(PFE)

Jul 18, 2001
Good short/long term growth potential. Great pipeline.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$41.01

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 12, 2001
Suspicious of large cap drug companies. High risk industry.
Photo of David BaskinDavid BaskinUnlock Rating
$37.60

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jun 20, 2001
A little high now. Buy below $40.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$44.50

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 14, 2001
(Was a top pick on Jan 8/01 up 2%) Prefers over Merck. Less patent expiries. In a good position with good pipeline.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$43.25

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 06, 2001
Likes both Pfizer and Merck in pharmaceuticals.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$42.85

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 05, 2001
Caution. At its FMV.
Photo of Ross HealyRoss HealyUnlock Rating
$42.95

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 28, 2001
Least amount of patent expiry. Have some good new product launches. Good pipeline.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$41.86

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 25, 2001
Always expensive, but a good pipeline. Long term.
Photo of John ZechnerJohn ZechnerUnlock Rating
$41.86

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 17, 2001
Prefers over Merck. No patent expiries.
Photo of John McCollJohn McCollUnlock Rating
$44.76

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 16, 2001
(Was a top pick on Apr 27/00 up 3.3%) Still likes.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$44.62

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 10, 2001
Great pipeline of drugs. Good synergies. Safe play. Price a little high.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.74

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 04, 2001
At a good price now. Good pipeline.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$43.46

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 03, 2001
At fair market value. Now ($45). No room to grow.
Photo of Ross HealyRoss HealyUnlock Rating
$42.25

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 25, 2001
(Was a top pick on Jan 8 down 3%) Still likes. Just bought more. Has the least amount of patent expiries.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.91

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 12, 2001
Long term. Strong growth/company.
Photo of Neil MurdockNeil MurdockUnlock Rating
$40.70

Stock price when the opinion was issued

$25.65

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 856 to 870 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PANW -10.64$269.79
GS 51.795$1092.8149
AAPL 0.67$310.93
BUG -0.365$36.405
ABBV 5.32$222.45

Today's Top Picks

CRWD -47.32$700.29
AMD -19.52$523
AVGO -70.07$409.16
TVE.TO 0.42$13.99
BHP -2.18$88.67

Popular Articles

Latest Sell Signals

AVGO -70.07$409.16
LDOS 1.85$126.2
CME 0$
ULTA -6.92$464.29
MRVL 10.32$311.97

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Bryn Talkington

Requisite Capital Management

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica